Merck & Co Inc Merck’s (NYSE: MRK) Molnupiravir Shows Reduction In Virus Infection Merck & Co., Inc. (NYSE: MRK) has reported positive results from its Phase 2a to assess the safety of Molnupiravir. MRK is developing Molnupiravir jointly with Ridgeback Bio.
Merck & Co Inc Merck (NYSE: MRK) Announces Acquisition Of Pandion Merck & Co., Inc. (NYSE: MRK) revealed that it has signed an agreement with Pandion to acquire the clinical-stage biotechnology firm. Merck will buy Pandion through its subsidiary for $60 per share in cash.
